TIM-3 and TIGIT are possible immune checkpoint targets in patients with bladder cancer.
TIM-3 and TIGIT are possible immune checkpoint targets in patients with bladder cancer.
复制标题
DOI：
10.1016/j.urolonc.2020.06.007
复制
发表时间：
2022-09
期刊：
影响因子：
--
通讯作者：
Sfakianos JP
中科院分区：
文献类型：
--
作者：
Attalla K;Farkas AM;Anastos H;Audenet F;Galsky MD;Bhardwaj N;Sfakianos JP
免疫疗法作为一种有效的抗癌策略的复兴，伴随着对潜在免疫途径的更成熟理解和新型免疫检查点靶标的开发。首先针对细胞毒性T淋巴细胞相关抗原4，后来针对程序性死亡1的抗体的临床开发在大量肿瘤类型的患者亚组中实现了持久的疾病控制。以前的工作表明，单独靶向程序性死亡1途径不会导致T细胞功能的完全恢复，并且在某些癌症中，靶向该轴根本不会恢复T细胞功能，这表明需要鉴定参与T细胞耗竭的其他分子和抑制途径。在膀胱癌患者的全面免疫分析研究中，我们证明了T细胞免疫球蛋白结构域和含粘蛋白结构域的分子以及T细胞免疫球蛋白和基于免疫受体酪氨酸的抑制性基序结构域作为可能的靶点，可能是单药治疗或与其他免疫检查点抑制剂联合治疗。
The resurgence of immunotherapy as an effective anticancer strategy has been coupled with more mature understandings of the underlying immune pathways and the development of novel immune checkpoint targets. The clinical development of antibodies first directed against cytotoxic T-lymphocyte–associated antigen 4, and later against program death 1, achieved durable disease control in a subset of patients across a large number of tumor types. Previous work demonstrates that targeting the programmed death 1 pathway alone does not result in complete restoration of T cell function and in some cancers, targeting this axis does not restore T cell function at all, suggesting a need to identify other molecules and inhibitory pathways that are involved in T cell exhaustion. In a comprehensive immune profiling study of patients with bladder cancer, we demonstrate T-cell immunoglobulin domain and mucin domain-containing molecule and T cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain as possible targets as perhaps monotherapy or in combination with other immune checkpoint inhibitors.
登录
查看更多内容
影响因子：
11.2
作者：
Fourcade J;Sun Z;Pagliano O;Chauvin JM;Sander C;Janjic B;Tarhini AA;Tawbi HA;Kirkwood JM;Moschos S;Wang H;Guillaume P;Luescher IF;Krieg A;Anderson AC;Kuchroo VK;Zarour HM
通讯作者：
Zarour HM
影响因子：
11.5
作者：
Nirschl, Christopher J.;Drake, Charles G.
通讯作者：
Drake, Charles G.
影响因子：
50.3
作者：
Johnston, Robert J.;Comps-Agrar, Laetitia;Grogan, Jane L.
通讯作者：
Grogan, Jane L.
影响因子：
3.4
作者：
Audenet F;Farkas AM;Anastos H;Galsky MD;Bhardwaj N;Sfakianos JP
通讯作者：
Sfakianos JP
DOI：
10.1084/jem.20100643
发表时间：
2010-09-27
期刊：
The Journal of experimental medicine
影响因子：
--
作者：
Sakuishi K;Apetoh L;Sullivan JM;Blazar BR;Kuchroo VK;Anderson AC
通讯作者：
Anderson AC